[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 18(3): 167-170. DOI:10.3760/cma.j.issn.1007-3418.2010.03.003. [2] CARR R M, ORANU A, KHUNGAR V. Nonalcoholic fatty liver disease: pathophysiology and management[J]. Gastroenterol Clin North Am, 2016, 45(4):639-652. DOI:10.1016/j.gtc.2016.07.003. [3] SWEET P H, KHOO T, NGUYEN S. Nonalcoholic Fatty Liver Disease[J]. Primary Care: Clinics in Office Practice, 2017, 44(4):599-607. DOI:10.1016/j.pop.2017.07.003. [4] SOMAYA A, ARUN S. Recent advances in understanding and managing non-alcoholic fatty liver disease[J]. F1000research, 2018, 7:720. DOI:10.12688/f1000research.14421.1. [5] PAREDES A H, TORRES D M, HARRISON S A. Nonalcoholic fatty liver disease.[J]. Clinics in Liver Disease, 2012, 16(2):397-419. DOI:10.1016/j.cld.2012.03.005. [6] NORBERT STEFAN M D, HANS-ULRICH HÄRINGMD, KENNETH CUSI MD, et al. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.[J]. The Lancet Diabetes Endocrinology, 2019, 7(4): 313-324. DOI:10.1016/S2213-8587(18)30154-2. [7] YASUHIKO M, RIEKO K, TOSHIHIRO I, et al. Predominant expression of invariant Vα14+ TCR α chain in NK1.1+ T cell populations[J]. International Immunology,1995,7(7):1157-1161. DOI:10.1093/intimm/7.7.1157. [8] BROSSAY L, CHIODA M, BURDIN N, et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution[J]. The Journal of Experimental Medicine, 1998, 188(8): 1521-1528.. DOI: 10.1084/jem.188.8.1521. [9] SAKUISHI K, OKI S, ARAKI M, et al. Invariant NKT Cells Biased for IL-5 Production Act as Crucial Regulators of Inflammation[J]. Journal of Immunology, 2007, 179(6):3452-3462. DOI: 10.4049/jimmunol.179.6.3452. [10] CERUNDOLO V, SILK J D, MASRI S H, et al. Harnessing invariant NKT cells in vaccination strategies[J]. Nature Reviews Immunology,2009,9:28-38DOI: 10.1038/nri2451. [11] HEGDE S, CHEN X, KEATON J M, et al. NKT cells direct monocytes into a DC differentiation pathway[J]. Journal of Leukocyte Biology, 2007, 81(5): 1224-1235. DOI:10.1189/jlb.1206718. [12] KWON D I, LEE Y J. Lineage differentiation program of invariant natural killer T cells[J]. Immune Network, 2017, 17(6): 365. DOI:10.4110/in.2017.17.6.365. [13] HORIKOSHI M, GOTO D, SEGAWA S, et al. Activation of invariant NKT cells with glycolipid ligand α-galactosylceramide ameliorates glucose-6-phosphate isomerase peptide-induced arthritis[J]. PLoS ONE, 2012, 7(12):e51215. DOI:10.1371/journal.pone.0051215. [14] BARTHELEMY A, IVANOV S, HASSANE M, et al. Exogenous activation of invariant natural killer T cells by α-galactosylceramide reduces pneumococcal outgrowth and dissemination postinfluenza[J]. mBio, 2016, 7(6):e01440-16. DOI:10.1128/mBio.01440-16. [15] ZHANG Y, SPRINGFIELD R, CHEN S, et al. α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials[J]. Frontiers in Immunology, 2019, 10:1126-. DOI:10.3389/fimmu.2019.01126. [16] VAHEDI G, KANNO Y, FURUMOTO Y, et al. Super-enhancers delineate disease-associated regulatory nodes in T cells[J]. Nature, 2015, 520(7548):558-562. DOI:10.1038/nature14154. [17] MATSUDA J L, MALLEVAEY T, SCOTT-BROWNE J, et al. CD1d-restricted iNKT cells, the Swiss-Army knife of the immune system.[J]. Current Opinion in Immunology, 2008, 20(3):358-368. DOI:10.1016/j.coi.2008.03.018. [18] ZHU S, ZHANG H, BAI L. NKT cells in liver diseases[J]. Frontiers of Medicine, 2018, 12(3):249-261. DOI:10.1007/s11684-018-0622-3. [19] KUMAR, VIPIN. NKT-cell subsets: Promoters and protectors in inflammatory liver disease[J]. Journal of Hepatology, 2013, 59(3):618-620. DOI:10.1016/j.jhep.2013.02.032. [20] MENG M, CHEN S, GAO X, et al. Activation of invariant natural killer T cell subsets in C57BL/6J mice by different injection modes of α-galactosylceramide[J]. Iran J Allergy Asthma Immunol, 2020, 19(1): 35-44. DOI:10.18502/ijaai.v19i1.2416. [21] CHEN D Z, GAO X, WANG J G, et al. Activation of hepatic iNKT2 cells by α-GalCer ameliorates hepatic steatosis induced by high-fat diet in C57BL/6J mice[J]. Int Immunopharmacol, 2019, 74: 105727. DOI:10.1016/j.intimp.2019.105727. [22] TAKAHASHI Y, SOEJIMA Y, FUKUSATO T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. World J Gastroenterol, 2012, 18(19):2300-2308. DOI:10.3748/wjg.v18.i19.2300. [23] PATEL D P, YAN T, KIM D, et al. Withaferin A improves nonalcoholic steatohepatitis in mice[J]. Journal of Pharmacology and Experimental Therapeutics, 2019, 371(2): 360-374. DOI:10.1124/jpet.119.256792. [24] HEBBAED L, GEORGE J. Animal models of nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(1):35-44. DOI:10.1038/nrgastro.2010.191. [25] SUNG-BAE KIM, OK-HWA, YOUNG-SEOB Lee, et al. Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.[J]. PLOS ONE, 2016, 11(2):e0147745. DOI:10.1371/journal.pone.0147745 [26] AYAE IKAWA-YOSHIDA, SAORI MATSUO, ATSUHIKO KATO,et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet[J]. International Journal of Experimental Pathology, 2017,98(4): 221-233.. DOI:10.1111/iep.12240 [27] TAJIRI K, SHIMIZU Y. Role of NKT cells in the pathogenesis of NAFLD[J]. Int J Hepatol, 2012, 2012: 850836. DOI:10.1155/2012/850836. [28] SZCZEPANKIEWICZ D, SKRZYPSKI M, PRUSZYN 'SKA-OSZMAŁEK E, et al. Interleukin 4 affects lipid metabolism and the expression of pro-inflammatory factors in mature rat adipocytes[J]. Immunobiology, 2018, 223(11): 677-683. DOI:10.1016/j.imbio.2018.07.014. [29] WEISS S T. Obesity: insight into the origins of asthma[J]. Nat Immunol, 2005, 6(6): 537-539. DOI:10.1038/ni0605-537. ( |